To get a good looking data set for NSCLC is not easy at all.
That drug candidate of Blueprint Medicines is based on EGFR mutation, is not even competative to EFTI in terms of market coverage, let alone the think about of working mechanism.
For now, Blueprint is US$5B and Immutep is US$0.3B. We just need one de-risk readout to enable a proper market cap to be crowned, which is TACTI003 I think.
In 100-day count down now?
To get a good looking data set for NSCLC is not easy at all.That...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.010(2.44%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 42.5¢ | 41.0¢ | $882.4K | 2.121M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54134 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 16576 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
42.0¢ |
Change
0.010 ( 1.40 %) |
||||
| Open | High | Low | Volume | ||
| 41.0¢ | 42.3¢ | 41.0¢ | 441363 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| IMM (ASX) Chart |
